Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimzation studies.
Technology that eliminates daily pill taking, and with it "pill fatigue," stigma and other barriers to adherence, has already proven its value, and is on the horizon for HIV.
Women with HIV tend to perform worse than HIV-negative women on cognitive performance tests, even after many years on treatment, new research finds -- but trends differed depending on the test and on women's treatment success.
Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.
A regimen consisting of only two drugs, the integrase inhibitor dolutegravir (Tivicay) and the NNRTI rilpivirine (Edurant), held up well as a maintenance approach in people with HIV who switched from more complex regimens.
At CROI 2017, Richard Kroup, M.D., from NIAID provided an overview of the recent advances in antibody treatments for HIV prevention and treatment.
Here's a preview of some of the noteworthy HIV cure and treatment research being presented at CROI 2017 in Seattle.
A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.
If an HIV-positive patient's viral load test results come back between 50 copies/mL and 200 copies/mL, consider retesting the same blood sample, Joseph Eron Jr., M.D., recommends. New study results suggest that the retest results may alter a clinicia...
When it comes to an HIV cure, what do we know now and what are the main areas of focus for future research? Irini Sereti, M.D., reviewed and analyzed the current strategies in cure research, during a presentation at IDWeek 2016 in New Orleans.